Back to Search
Start Over
Trabectedin as second line and beyond in advanced leiomyosarcoma
- Source :
- Journal of Clinical Oncology. 32:e21522-e21522
- Publication Year :
- 2014
- Publisher :
- American Society of Clinical Oncology (ASCO), 2014.
-
Abstract
- e21522 Background: Trabectedin is approved in the European Union for patients (pts) with advanced soft tissue sarcoma (STS) after failure of anthracyclines or ifosfamide. Methods: Consecutive pts w...
- Subjects :
- Leiomyosarcoma
Cancer Research
medicine.medical_specialty
Ifosfamide
business.industry
Soft tissue sarcoma
macromolecular substances
medicine.disease
Surgery
carbohydrates (lipids)
stomatognathic diseases
Second line
Oncology
otorhinolaryngologic diseases
medicine
bacteria
media_common.cataloged_instance
European union
business
Trabectedin
medicine.drug
media_common
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 32
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........799bfca9966cfe5af0a492cc5e115235
- Full Text :
- https://doi.org/10.1200/jco.2014.32.15_suppl.e21522